Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD 1.992
+0.007 (0.35%)
Apr 8, 2026, 12:59 PM AEST
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
1.21M AUD
Profits / Employee
-1.75M AUD
Market Cap
2.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mesoblast News
- 1 day ago - Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter - GlobeNewsWire
- 21 days ago - Mesoblast to Host R&D Day on April 8, 2026 - GlobeNewsWire
- 27 days ago - Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast - GlobeNewsWire
- 5 weeks ago - Ryoncil® Profits Underpinning Substantial Growth Pipeline - GlobeNewsWire
- 6 weeks ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 7 weeks ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga
- 7 weeks ago - High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD - GlobeNewsWire
- 2 months ago - Ryoncil® Net Revenues Increase for the Quarter to US$30M - GlobeNewsWire